Biofilms are structured multicellular bacterial communities encased in a protective extracellular polymeric substance (EPS) matrix, contributing significantly to antibiotic resistance and chronic infections. Biofilms undergo a multi-stage formation process, including reversible and irreversible attachment, microcolony development, maturation, and dispersal, with quorum sensing playing a vital role in intercellular communication. Biofilms are involved in a wide spectrum of diseases across various systems, such as otitis media, atherosclerosis, chronic rhinosinusitis, and urinary tract infections. They present unique challenges in treatment due to their heightened resistance to antibiotics, enabled by reduced growth rates, drug penetration, and the presence of persister cells. Emerging therapeutic strategies, including bacteriophage therapy, biofilm disruptors, nanotechnology, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene editing, host-directed therapies, and advanced coatings for medical devices, represent promising avenues for overcoming biofilm-associated complications. Despite these advancements, biofilm-associated infections remain a significant clinical challenge, particularly in hospital settings that exacerbate antimicrobial resistance and patient morbidity. Continued research focusing on biofilm-specific gene expression, prevention strategies, and innovative treatment approaches is critical to improving the management of biofilm-associated diseases and mitigating their impact on human health.